

Emanuela Risi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6849200/publications.pdf>

Version: 2024-02-01

42
papers

785
citations

567144

15
h-index

526166

27
g-index

42
all docs

42
docs citations

42
times ranked

1738
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 666.	1.3	113
2	Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. <i>Annals of Oncology</i> , 2018, 29, 1748-1754.	0.6	76
3	Clinical and Pathological Features of Primary Neuroectodermal Tumor/Ewing Sarcoma of the Kidney. <i>Urology</i> , 2013, 82, 382-386.	0.5	65
4	Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population. <i>Clinical Cancer Research</i> , 2017, 23, 1422-1431.	3.2	65
5	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. <i>Breast Care</i> , 2017, 12, 304-308.	0.8	53
6	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2131-2139.	3.2	40
7	Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer. <i>Cancers</i> , 2014, 6, 2187-2223.	1.7	34
8	Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. <i>Clinical Breast Cancer</i> , 2017, 17, 601-610.e2.	1.1	30
9	Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. <i>Breast</i> , 2018, 37, 142-147.	0.9	29
10	Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. <i>Oncologist</i> , 2015, 20, 880-889.	1.9	26
11	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. <i>Cancer Treatment Reviews</i> , 2019, 74, 29-34.	3.4	23
12	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687.	1.8	23
13	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	2.2	19
14	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
15	Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis. <i>PLoS ONE</i> , 2016, 11, e0157751.	1.1	17
16	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 329-341.	1.1	17
17	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	14
18	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. <i>Breast Cancer Research</i> , 2021, 23, 38.	2.2	14

#	ARTICLE	IF	CITATIONS
19	A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2 ⁻) metastatic breast cancer (mBC) (TREnd trial).. Journal of Clinical Oncology, 2017, 35, 1002-1002.	0.8	14
20	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. Npj Breast Cancer, 2019, 5, 26.	2.3	12
21	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 392-398.	1.1	12
22	Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib. International Journal of Dermatology, 2012, 51, 221-222.	0.5	11
23	Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules. Oncology, 2013, 84, 92-99.	0.9	9
24	PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. Npj Breast Cancer, 2022, 8, 24.	2.3	9
25	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biology and Therapy, 2012, 13, 1001-1008.	1.5	6
26	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. Breast Cancer Research, 2020, 22, 83.	2.2	6
27	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	1.4	6
28	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591881559.	1.4	5
29	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. Anticancer Research, 2018, 38, 4839-4845.	0.5	5
30	Using CTCs for pharmacogenomic analysis. Pharmacological Research, 2016, 106, 92-100.	3.1	4
31	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	2.3	4
32	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06). Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989160.	1.4	3
33	No pain, no gain What we can learn from a trial reporting negative results. Annals of Oncology, 2017, 28, 678-680.	0.6	2
34	PO62 FIRST LINE TRASTUZUMAB-BASED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PRESENTING WITH DE NOVO OR RECURRENT DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY. Breast, 2015, 24, S43.	0.9	0
35	Systemic Treatment of Metastatic Breast Cancer (MBC) in Older Adults. Breast, 2017, 36, S24.	0.9	0
36	LEPTOMENINGEAL DISEASE: AN UPDATE. Breast, 2019, 48, S28-S29.	0.9	0

#	ARTICLE	IF	CITATIONS
37	Treatment (T) of metastatic colorectal cancer (mCRC) patients (pts) ≥75 years (y) old in clinical practice: A multicenter analysis.. Journal of Clinical Oncology, 2014, 32, e14514-e14514.	0.8	0
38	First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease.. Journal of Clinical Oncology, 2015, 33, e11575-e11575.	0.8	0
39	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570.	0.8	0
40	Abstract 4416: Plasma thymidine kinase activity in patients with luminal metastatic breast cancer treated with Palbociclib within the phase II TReND trial. , 2019, , .		0
41	Abstract P5-06-11: Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC). , 2020, , .		0
42	Abstract P5-13-13: <i>PIK3CA</i> mutations co-occurring with copy number gain identify patients with adverse outcome and potentially different treatment sensitivity among hormone receptor positive and HER2 negative metastatic breast cancer. Cancer Research, 2022, 82, P5-13-13-P5-13-13.	0.4	0